Skip to main content
Clinical Trials/NCT06253884
NCT06253884
Not Yet Recruiting
N/A

A Prospective Pilot Study to Evaluate the Safety, Tolerability and Technical Feasibility of Utilizing Carbon Dioxide (CO2) for Assessing Coronary Blood Flow in Subjects With Coronary Artery Disease

Indiana University1 site in 1 country30 target enrollmentJanuary 10, 2026

Overview

Phase
N/A
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
Indiana University
Enrollment
30
Locations
1
Primary Endpoint
Ratio of Maximum Signal Intensity (MSI) by BOLD MRI
Status
Not Yet Recruiting
Last Updated
8 months ago

Overview

Brief Summary

This is a prospective pilot study to evaluate the safety, tolerability and technical feasibility of utilizing carbon dioxide for assessing coronary blood flow in subjects with coronary artery disease.

Detailed Description

The purpose of this study is to noninvasively assess changes in the heart's blood flow through inducing changes in the amount of carbon dioxide in the participant's blood and having them breathe various combinations of carbon dioxide and oxygen.

Registry
clinicaltrials.gov
Start Date
January 10, 2026
End Date
July 15, 2027
Last Updated
8 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Rohan Dharmakumar

Executive Director, Krannert Cardiovascular Research Center

Indiana University School of Medicine

Eligibility Criteria

Inclusion Criteria

  • Adults \> 18 years of age
  • Clinically stable individuals with suspected or known coronary artery disease (CAD)
  • The SPECT/PET study indicates at least a mild to moderate myocardial ischemia (\>5-9%) or fractional-flow-reserve (FFR) of \<0.75.

Exclusion Criteria

  • Prior myocardial infarction by clinical history (subjects with prior coronary revascularization without myocardial infarction will not be excluded)
  • Hypotension (systolic blood pressure \< 100 mmHg)
  • Significant non-coronary cardiac disease (e.g., valvular abnormality, or cardiomyopathy, etc.)
  • Inability to schedule the research study within 30 days of the SPECT/PET study and prior to any coronary revascularization procedure
  • Inability to voluntarily increase their breathing rate if prompted to do so
  • Persons with mechanically, magnetically, or electrically activated implants (such as cardiac pacemakers, neurostimulators, and infusion pumps), with ferromagnetic implants or foreign bodies (such as intracranial, aneurysm clips, shrapnel, and intraocular metal chips)
  • Persons who are pregnant, nursing, or implanted with intrauterine devices (IUD's)
  • Persons with a history of significant heart, lung, kidney, or liver disease
  • Persons with asthma
  • Persons who have abnormal cardiac rhythm and rate

Outcomes

Primary Outcomes

Ratio of Maximum Signal Intensity (MSI) by BOLD MRI

Time Frame: 3 hours

Maximum Signal Intensity (MSI) quantification will be measured through myocardial perfusion by blood oxygen level dependent (BOLD) MRI. The ratio of MSI in hypercarbia vs normocarbia will be evaluated in the 17-segment LV model.

Ratio of Maximum Signal Intensity (MSI) by FFP MRI

Time Frame: 3 hours

Maximum Signal Intensity (MSI) quantification will be measured through myocardial perfusion by first pass perfusion (FFP) MRI. The ratio of MSI in hypercarbia vs normocarbia will be evaluated in the 17-segment LV model.

Study Sites (1)

Loading locations...

Similar Trials